门冬胰岛素与生物合成人胰岛素在妊娠期糖尿病治疗中的疗效对比  

Comparison of the Efficacy of Insulin Aspart and Biosynthetic Human In⁃sulin in the Treatment of Gestational Diabetes Mellitus

作　　者：黄秋香 陈聪红 陈伟凤 HUANG Qiuxiang;CHEN Conghong;CHEN Weifeng(Quanzhou First Hospital,Quanzhou 362000,Fujian,China)

机构地区：[1]泉州市第一医院,福建泉州362000

出　　处：《糖尿病新世界》2024年第21期49-52,共4页Diabetes New World

摘　　要：目的探究妊娠期糖尿病(gestational diabetes mellitus,GDM)治疗中门冬胰岛素与生物合成人胰岛素的临床应用价值。方法回顾性选取2023年3月—2024年2月泉州市第一医院收治的120例GDM患者的临床资料,根据治疗方式的不同分成对照组、观察组,各60例,两组患者分别采取生物合成人胰岛素、门冬胰岛素治疗,比较两组糖代谢水平、不良妊娠结局发生情况、临床疗效。结果治疗后,观察组各项血糖指标水平均低于对照组,治疗总有效率高于对照组,差异均有统计学意义(P均<0.05)。两组患者不良妊娠结局总发生率比较,差异无统计学意义(P>0.05)。结论GDM患者治疗中门冬胰岛素应用效果优于生物合成人胰岛素,控糖效果更佳,临床疗效显著。Objective To explore the clinical application value of insulin aspart and biosynthetic human insulin in the treatment of gestational diabetes mellitus(GDM).Methods The clinical data of 120 patients with GDM admitted to Quanzhou First Hospital from March 2023 to February 2024 were retrospectively selected and divided into control group and observation group according to different treatment methods,with 60 cases in each group.The patients in the two groups were treated with biosynthetic human insulin and insulin aspart,respectively.The glucose metabolism lev-els,adverse pregnancy outcomes and clinical efficacy of the two groups were compared.Results After treatment,the levels of blood glucose indexes in the observation group were lower than those in the control group,and the total effec-tive rate of treatment was higher than that of the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse pregnancy outcomes between the two groups(P>0.05).Conclusion Insulin aspart is more effective than biosynthetic human insulin in the treatment of GDM patients,with better glycemic control and significant clinical efficacy.

关 键 词：妊娠期糖尿病 门冬胰岛素 生物合成人胰岛素 糖代谢水平 妊娠结局 

分 类 号：R714[医药卫生—妇产科学]